ADARB2 and glioblastoma: The expression of ADAR3 was shown to have a negative correlation with the development of GBM grade, to be greater in neural subtype and IDH1/2 mutant tumors, and to be linked with better outcomes in patients identified as having lower-grade GBM (LGG) (98).